Entecavir

A potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Entecavir has demonstrated safety and efficacy in the treatment of chronic hepatitis B infection. It is the prototype for the cyclopentane class of nucleoside/nucleotide chronic hepatitis B antiviral agents. It has a high potency and, due to its structural formula and mechanism of action, entecavir is associated with emergence of minimal resistance in the long-term treatment of nucleoside-naive patients. Research suggests that long-term treatment may be required for chronic hepatitis B patients, especially those who acquire HBV early in life, to achieve maximum viral suppression and improve outcomes. Several recent studies have evaluated the long-term safety, efficacy and development of resistance in nucleoside-naive patients treated with entecavir. Results indicate that the long-term use of entecavir is well tolerated and associated with continuous clinical improvement-with an increasing number of patients achieving undetectable levels of HBV DNA, HBeAg seroconversion and minimal resistance. These data underscore the position of entecavir for first-line therapy and highlight its role in the long-term treatment of chronic hepatits B.

Original languageEnglish
Pages (from-to)569-579
Number of pages11
JournalExpert Review of Anti-Infective Therapy
Volume6
Issue number5
DOIs
Publication statusPublished - 2008 Oct 1

Fingerprint

Chronic Hepatitis B
Nucleosides
Antiviral Agents
Safety
Cyclopentanes
Hepatitis B e Antigens
Therapeutics
Nucleotides
entecavir
DNA
Infection
Research

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Microbiology (medical)
  • Infectious Diseases
  • Virology

Cite this

@article{b16d1ddbf53a46faa0e4e4108739cee2,
title = "Entecavir: A potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients",
abstract = "Entecavir has demonstrated safety and efficacy in the treatment of chronic hepatitis B infection. It is the prototype for the cyclopentane class of nucleoside/nucleotide chronic hepatitis B antiviral agents. It has a high potency and, due to its structural formula and mechanism of action, entecavir is associated with emergence of minimal resistance in the long-term treatment of nucleoside-naive patients. Research suggests that long-term treatment may be required for chronic hepatitis B patients, especially those who acquire HBV early in life, to achieve maximum viral suppression and improve outcomes. Several recent studies have evaluated the long-term safety, efficacy and development of resistance in nucleoside-naive patients treated with entecavir. Results indicate that the long-term use of entecavir is well tolerated and associated with continuous clinical improvement-with an increasing number of patients achieving undetectable levels of HBV DNA, HBeAg seroconversion and minimal resistance. These data underscore the position of entecavir for first-line therapy and highlight its role in the long-term treatment of chronic hepatits B.",
author = "Pin-Nan Cheng and Ting-Tsung Chang",
year = "2008",
month = "10",
day = "1",
doi = "10.1586/14787210.6.5.569",
language = "English",
volume = "6",
pages = "569--579",
journal = "Expert Review of Anti-Infective Therapy",
issn = "1478-7210",
publisher = "Expert Reviews Ltd.",
number = "5",

}

TY - JOUR

T1 - Entecavir

T2 - A potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients

AU - Cheng, Pin-Nan

AU - Chang, Ting-Tsung

PY - 2008/10/1

Y1 - 2008/10/1

N2 - Entecavir has demonstrated safety and efficacy in the treatment of chronic hepatitis B infection. It is the prototype for the cyclopentane class of nucleoside/nucleotide chronic hepatitis B antiviral agents. It has a high potency and, due to its structural formula and mechanism of action, entecavir is associated with emergence of minimal resistance in the long-term treatment of nucleoside-naive patients. Research suggests that long-term treatment may be required for chronic hepatitis B patients, especially those who acquire HBV early in life, to achieve maximum viral suppression and improve outcomes. Several recent studies have evaluated the long-term safety, efficacy and development of resistance in nucleoside-naive patients treated with entecavir. Results indicate that the long-term use of entecavir is well tolerated and associated with continuous clinical improvement-with an increasing number of patients achieving undetectable levels of HBV DNA, HBeAg seroconversion and minimal resistance. These data underscore the position of entecavir for first-line therapy and highlight its role in the long-term treatment of chronic hepatits B.

AB - Entecavir has demonstrated safety and efficacy in the treatment of chronic hepatitis B infection. It is the prototype for the cyclopentane class of nucleoside/nucleotide chronic hepatitis B antiviral agents. It has a high potency and, due to its structural formula and mechanism of action, entecavir is associated with emergence of minimal resistance in the long-term treatment of nucleoside-naive patients. Research suggests that long-term treatment may be required for chronic hepatitis B patients, especially those who acquire HBV early in life, to achieve maximum viral suppression and improve outcomes. Several recent studies have evaluated the long-term safety, efficacy and development of resistance in nucleoside-naive patients treated with entecavir. Results indicate that the long-term use of entecavir is well tolerated and associated with continuous clinical improvement-with an increasing number of patients achieving undetectable levels of HBV DNA, HBeAg seroconversion and minimal resistance. These data underscore the position of entecavir for first-line therapy and highlight its role in the long-term treatment of chronic hepatits B.

UR - http://www.scopus.com/inward/record.url?scp=55249118410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55249118410&partnerID=8YFLogxK

U2 - 10.1586/14787210.6.5.569

DO - 10.1586/14787210.6.5.569

M3 - Article

VL - 6

SP - 569

EP - 579

JO - Expert Review of Anti-Infective Therapy

JF - Expert Review of Anti-Infective Therapy

SN - 1478-7210

IS - 5

ER -